Lineage Cell Therapeutics Inc (LCTX) — Free Cash Flow Generation Index
Lineage Cell Therapeutics Inc (LCTX) has a Free Cash Flow Generation Index of 1.00x as of March 2022. Free cash flow of $21.86 Million represents 1% of operating cash flow ($21.90 Million). Explore Lineage Cell Therapeutics Inc capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Lineage Cell Therapeutics Inc Free Cash Flow Generation Index (2022–2022)
Historical FCF Generation Index trend for Lineage Cell Therapeutics Inc across 1 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Lineage Cell Therapeutics Inc.
Annual Free Cash Flow Generation for Lineage Cell Therapeutics Inc (2022–2022)
Year-by-year Free Cash Flow Generation Index for Lineage Cell Therapeutics Inc. Check Lineage Cell Therapeutics Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
| Year | FCG Index | Free Cash Flow (USD) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2022 | 0.61x | $646.00K | $1.06 Million | $413.00K | — |